Comparative lesion sequencing provides insights into tumor evolution - PubMed (original) (raw)

Comparative Study

. 2008 Mar 18;105(11):4283-8.

doi: 10.1073/pnas.0712345105. Epub 2008 Mar 12.

Wei-Dong Chen, Giovanni Parmigiani, Frank Diehl, Niko Beerenwinkel, Tibor Antal, Arne Traulsen, Martin A Nowak, Christopher Siegel, Victor E Velculescu, Kenneth W Kinzler, Bert Vogelstein, Joseph Willis, Sanford D Markowitz

Affiliations

Comparative Study

Comparative lesion sequencing provides insights into tumor evolution

Siân Jones et al. Proc Natl Acad Sci U S A. 2008.

Abstract

We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common. When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize; (ii) it requires few, if any, selective events to transform a highly invasive cancer cell into one with the capacity to metastasize; (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells. These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Under separate licensing agreements between The Johns Hopkins University and Exact Sciences Corporation and Genzyme Corporation Oncology, V.E.V., K.W.K., and B.V are entitled to a share of royalty received by the University on sales of products described in this article/presentation. V.E.V., K.W.K., and B.V and the University own Genzyme Molecular Oncology stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by The Johns Hopkins University in accordance with its conflict of interest policies.

Figures

Fig. 1.

Fig. 1.

Major genetic alterations associated with colorectal tumorigenesis. See

SI Methods

for further explanation.

Fig. 2.

Fig. 2.

Representative examples of sequencing chromatograms of DNA from a xenograft, from the metastatic lesion from which the xenograft was derived, and from the patient's normal cells. Note that the ratio of the mutant to wild-type allele in the xenograft is higher than that in the metastatic lesion because the latter represented a mixture of neoplastic and nonneoplastic cells (stroma, white blood cells, etc.). The arrow points to the mutated base.

Fig. 3.

Fig. 3.

Histopathology of representative lesions. (A) Primary invasive moderately differentiated adenocarcinoma (enclosed by black boundary) arising in a tubular adenoma (enclosed by red boundary) from patient 10. (B) Primary invasive moderately differentiated adenocarcinoma (enclosed by black boundary) with adjacent nonneoplastic colonic mucosa (enclosed by red boundary) from patient 2. (C) Metastatic adenocarcinoma (enclosed by black boundary) to liver (enclosed by red boundary) derived from primary colon adenocarcinoma of patient 2. All sections were stained with H&E, and the tissues within each boundary were separately microdissected.

Fig. 4.

Fig. 4.

Representative examples of BEAMing assays from the indicated patients and lesions. In patient 13, the mutation shown represents one that was present in a new metastasis that occurred 29 months after chemotherapy (see Application to Individual Patients). The red dots correspond to beads attached to mutant DNA fragments [labeled with phycoerythrin (PE)], the blue dots correspond to beads attached to WT DNA fragments [labeled with fluorescein (FITC)], and the black dots correspond to beads attached to both WT and mutant DNA fragments.

Fig. 5.

Fig. 5.

Evolution of a lethal cancer. Each cell-filled cone represents one or more clonal expansions (see

SI Methods

for details). The times required for the evolution of the large adenoma founder cell to an advanced carcinoma founder cell (ΔLAd,ACa) and evolution of the advanced carcinoma founder cell to metastatic founder cell (ΔACa,Met) were determined by comparative lesion sequencing. Other intervals, such as the time (_T_exp) required for the expansion of the metastasis founder cell FCellMet to the size detected in our patients, were estimated as described in

SI Methods

. The model posits that there are at least two clonal expansions, denoted by question marks, that are not associated with any known genetic alterations.

Similar articles

Cited by

References

    1. Kinzler KW, Vogelstein B. Lessons from hereditary colon cancer. Cell. 1996;87:159–170. - PubMed
    1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767. - PubMed
    1. Vogelstein B, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532. - PubMed
    1. Markowitz S, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336–1338. - PubMed
    1. Thiagalingam S. Evaluation of chromosome 18q in colorectal cancers. Nat Genet. 1996;13:343–346. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources